Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ocugen: Q2 Earnings Snapshot AP - Thu Aug 6, 6:22AM CDT

Ocugen: Q2 Earnings Snapshot

OCGN : 1.4000 (+2.19%)
Ocugen Provides Business Update with Second Quarter 2026 Financial Results GlobeNewswire - Thu Aug 6, 6:02AM CDT

Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related...

OCGN : 1.4000 (+2.19%)
Ocugen: Gene Therapy Pipeline Meets Reality in Thursday's Report Barchart - Wed Aug 5, 4:23PM CDT

Barchart Research What to Expect from OCGN Earnings OCGN Generated August 5, 2026 Current Price $1.2800 EPS Estimate $$-0.05 Consensus Rating Strong Buy Average Move 6.03% Ocugen: Gene Therapy Pipeline...

OCGN : 1.4000 (+2.19%)
Ocugen to Participate in Upcoming August Investor Conferences GlobeNewswire - Fri Jul 31, 6:02AM CDT

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.4000 (+2.19%)
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration GlobeNewswire - Wed Jul 29, 6:01AM CDT

RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet need The designation could accelerate...

OCGN : 1.4000 (+2.19%)
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results GlobeNewswire - Tue Jul 28, 3:01PM CDT

MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it...

OCGN : 1.4000 (+2.19%)
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa GlobeNewswire - Mon Jul 13, 6:02AM CDT

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa.,...

OCGN : 1.4000 (+2.19%)
Ocugen to Participate in Upcoming July Industry Conferences GlobeNewswire - Wed Jul 1, 6:00AM CDT

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.4000 (+2.19%)
Ocugen to Participate in Upcoming June Investor and Industry Conferences GlobeNewswire - Tue Jun 2, 6:03AM CDT

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.4000 (+2.19%)
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes GlobeNewswire - Thu May 14, 3:30PM CDT

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing...

OCGN : 1.4000 (+2.19%)

Barchart Exclusives

Dear HP Stock Fans, Mark Your Calendars for August 26 Barchart - 8 minutes ago
HP’s strong growth faces a key test as rising component costs threaten to pressure profits despite growing AI PC adoption. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.